Treatment for Polycythemia Vera
Universal First-Line Therapy
All patients with polycythemia vera require therapeutic phlebotomy to maintain hematocrit below 45% and low-dose aspirin (81 mg once or twice daily) unless contraindications exist. 1, 2, 3
Phlebotomy remains the cornerstone of therapy to reduce thrombotic risk by controlling red blood cell mass; the hematocrit target of <45% is non-negotiable for all patients. 2, 3
Aspirin (81 mg daily) prevents arterial and venous thrombosis, which occurs in 16% (arterial) and 7% (venous) of patients at or before diagnosis, often in unusual sites like splanchnic veins. 2
Withhold aspirin only if active bleeding is present, extreme thrombocytosis (≥1000 × 10⁹/L) with acquired von Willebrand disease exists, or the patient has documented aspirin intolerance. 4, 2
Aggressively manage all cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking) as these compound the inherent thrombotic risk of PV. 1
Risk Stratification for Cytoreductive Therapy
High-risk patients (age ≥60 years OR prior thrombosis history) require cytoreductive therapy in addition to phlebotomy and aspirin. 1, 2, 3
Low-risk patients (age <60 years AND no thrombosis history) should receive cytoreductive therapy once they reach age 60 or develop a major thrombotic complication. 1
Consider cytoreductive therapy in low-risk patients with persistent, severe PV-related symptoms (intractable pruritus, marked splenomegaly, poor phlebotomy tolerance) despite optimal supportive care. 2, 3
First-Line Cytoreductive Therapy
Hydroxyurea is the preferred first-line cytoreductive agent for high-risk patients, though caution is warranted in young patients requiring decades of treatment. 1, 3
Hydroxyurea effectively reduces thrombosis risk, normalizes blood counts, and controls splenomegaly in the majority of patients. 2, 3
Exercise caution when prescribing hydroxyurea to patients under age 40-50 due to theoretical long-term leukemogenic concerns, though definitive evidence is lacking. 1
Interferon-alpha (including pegylated formulations) represents an alternative first-line option, particularly for younger patients who need long-term cytoreduction, as it can induce molecular responses and reduce JAK2V617F allele burden. 1, 3, 5
Second-Line Therapy for Hydroxyurea Failure
Ruxolitinib is strongly recommended for patients who are resistant to or intolerant of hydroxyurea, with FDA and EMA approval based on the RESPONSE trials. 1, 5
Approximately 24% of patients develop hydroxyurea resistance or intolerance, which increases their risk of death, myelofibrosis transformation, and acute myeloid leukemia. 6, 5
Both ruxolitinib and interferon-alpha are appropriate second-line options; choose based on patient age (prefer interferon in young patients) and drug availability. 1
Ruxolitinib provides superior hematocrit control, reduces spleen size, normalizes blood counts, and improves PV-related symptoms compared to best available therapy in hydroxyurea-refractory patients. 1, 6, 5
The recommendation for ruxolitinib is strong despite moderate-quality evidence from the RESPONSE trials, which had performance bias and comparator indirectness issues. 1
Reserve ruxolitinib for true hydroxyurea failure or severe, refractory symptoms (protracted pruritus, marked splenomegaly unresponsive to other agents) rather than routine use. 3
Alternative Cytoreductive Options
Busulfan may be considered in very elderly patients as intermittent dosing, though it is not a preferred agent due to leukemogenic potential. 1
Interferon-alpha can induce durable hematologic and molecular responses, with some patients achieving significant reductions or even eradication of JAK2V617F mutation. 5
Weigh interferon-alpha toxicities (flu-like symptoms, depression, autoimmune phenomena) against disease control benefits on a case-by-case basis. 5
Perioperative Management
For emergency surgery in newly diagnosed PV, proceed without delay; the risk of postponing life-saving surgery outweighs hematologic abnormalities. 4
Do not postpone emergency surgery to achieve hematocrit <45%; this target is only feasible for elective procedures with at least 3 months of preparation. 4
For elective surgery, maintain hematocrit <45% for at least 3 months preoperatively to minimize thrombotic risk. 4
Discontinue aspirin 1 week before elective surgery; in emergencies, proceed without aspirin and resume 24 hours postoperatively once hemostasis is confirmed. 4
Start prophylactic low-molecular-weight heparin 12-24 hours after surgery once surgical hemostasis is secured; delay 48-72 hours for high-bleeding-risk procedures. 4
Continue or initiate hydroxyurea perioperatively unless the surgical team objects; cytoreductive therapy can be maintained throughout the perioperative period. 4
Monitoring and Long-Term Considerations
Monitor for thrombotic complications (deep vein thrombosis, pulmonary embolism, arterial occlusion, splanchnic vein thrombosis) and hemorrhagic events, especially with extreme thrombocytosis. 4, 2
Median survival from diagnosis ranges from 14-27 years, with younger patients (age ≤40) achieving 35-37 years of survival. 2, 3
Approximately 12.7% of patients develop myelofibrosis and 6.8% develop acute myeloid leukemia over time; leukemic transformation rates at 10 years are approximately 3%. 2, 3
Certain mutations (spliceosome genes) and abnormal karyotype may compromise survival in PV, though driver mutations (JAK2, CALR, MPL) do not directly affect survival in most studies. 3